Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.47 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | GSK3A | P49840 | 4/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051062 | 0.85 | ADORA2B (0.63) | ADORA2AADORA1GSK3BGSK3AADORA2B | |
| SCHEMBL4048967 | 0.84 | ADORA1 (0.49) | ADORA2AADORA1GSK3BGSK3AADORA2B | |
| SCHEMBL2928014 | 0.83 | MAPK14 (0.46) | GSK3BGSK3APIK3CA | |
| SCHEMBL1385324 | 0.80 | TOP2A (0.43) | ADORA2AGSK3BGSK3AADORA3PIK3CA | |
| SCHEMBL27618729 | 0.79 | PIK3CA (0.41) | GSK3BGSK3APIK3CA | |
| SCHEMBL4054613 | 0.76 | ADORA2B (0.67) | ADORA2AADORA1ADORA2BADORA3KDM4E | |
| SCHEMBL3076250 | 0.74 | ADORA2B (0.66) | ADORA2AADORA1ADORA2BADORA3PIK3CA | |
| SCHEMBL4049370 | 0.74 | ADORA2B (0.47) | ADORA2AADORA1GSK3BADORA2BADORA3 | |
| SCHEMBL4049926 | 0.71 | KDM4E (0.45) | ADORA2AADORA1ADORA2BADORA3KDM4E | |
| SCHEMBL4053202 | 0.70 | ADORA2B (0.60) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | claimed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| EP-1735310-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005100353-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA, SA (ES) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885GSK3B 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.